Merus (MRUS) announced that the first patient has been dosed in the company’s phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated metastatic colorectal cancer. Petosemtamab is a Biclonics targeting EGFR and LGR5. The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus price target raised to $97 from $89 at Citi
- 3 Best Stocks to Buy Now, 12/6/2024, According to Top Analysts
- Merus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLC
- Merus’ zenocutuzumab-zbco granted accelerated approval by FDA
- Merus price target lowered to $109 from $111 at Guggenheim